



DEEP HEALTH AI INDIA LIMITED

(Formerly known as "Deep Diamond India Limited") CIN: L24100RJ1994PLC112895

Regd. Office: 506-509 fifth floor, Apeksha, Plot No. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001) **Tel:** 0294-3569097.

E-mail: deephealthaiindia@gmail.com Website: www.deephealthaiindia.com

Date: August 13, 2026

To,
The Manager,
BSE Limited
Address: Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400001.

Scrip Code: 539559

Subject: Submission of Outcome of Board Meeting in compliance with the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Dear Sir/Madam,

This is to inform you that pursuant to Regulation 30 of the Listing Regulations, the Board at its meeting held today i.e. Thursday, August 13, 2026, inter alia, considered and approved the following:

1. Un-Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2026, along with draft Limited Review Report pursuant to Regulation 33 of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further, the Trading Window for dealing in shares of the Company has already been closed for all Directors/ KMPs/Designated Employees/ Connected Person of the Company from July 01, 2026, and will remain closed up to 48 (Forty-Eight) hours after the declaration of Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (both days inclusive) in accordance with SEBI (Prohibition of Insider Trading) Regulation, 2015 and the Company's Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders.

The Board Meeting commenced at 3:00 P.M and concluded at 3.40 P.M.

Kindly take the same on your records.

FOR DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

Narayan Singh Rathore
Managing Director
DIN: 10900646
Place: Udaipur



VRSK & Co. LLP

CHARTERED ACCOUNTANTS

1008, Ajmera Sikova, Opp. Damodar Park, LBS Marg, Ghatkopar (West) Mumbai - 400086
Phone: +91-22-35736454 | Mob: +91-9820572292 | Email: sureshk18@gmail.com

Independent Auditor's Limited Review Report

To,
The Board of Directors,
Deep Health AI India Limited

"We have reviewed the accompanying statement of unaudited quarterly financial results of M/s **Deep Health AI India Limited** ('the Company'), for the period ended 30th June, 2026 ('the Statement') being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. This statement which is the responsibility of the Company's Management and approved by Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India". This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquire of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement is prepared, in all material aspects, in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement or that it has not been prepared in accordance with the relevant prudential norms issued by Reserve Bank of India in respect of income recognition, asset classification, provisioning and other related matters.

For **VRSK & CO. LLP**
(Formerly known as V.R.S.K. & Co.)
CHARTERED ACCOUNTANTS
Firm Regn. No: 111426W/W100988

Suresh G. Kothari

Place : Mumbai
Date : August 13, 2026
UDIN : 26047625TSETNN5409

Suresh G. Kothari
Partner
Membership No: 047625



DEEP HEALTH AI INDIA LIMITED

Formerly Known as "DEEP DIAMOND INDIA LIMITED"

Regd. Office: 506-509, fifth floor, Apeksha, Plot No.256, Main Road, Hiran Magri, Sector-11, Udaipur, Rajasthan (313001)
CIN: L24100RJ1994PLC112895

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

Sr. No.	Particulars	(Rs. in Lakhs)			
		Quarter ended		Year ended	
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue from operations	45.00	25.00	15.00	425.00
	-Jewellery Business	-	-	-	-
	-Pharmaceutical Business	-	-	-	-
2	Other income	45.00	25.00	15.00	425.00
3	Total income (1+2)	16.61	18.22	18.68	424.02
		61.61	43.22	33.68	849.02
4	Expenses				
a)	Cost of material consumed	-	-	-	-
b)	Purchase of Stock -in-Trade	-	-	-	-
c)	Changes in inventories of finished goods work-in-progress and Stock -in-Trade	-	-	-	-
d)	Employee benefits expense	-	-	-	-
e)	Finance costs	4.81	5.89	4.14	18.81
f)	Depreciation	0.70	0.73	0.74	2.71
g)	Other expenses	0.12	0.13	0.27	0.78
	Total expenses	245.88	13.74	16.06	72.64
5	Profit/ (Loss) before exceptional items and tax (3-4)	251.51	20.49	21.21	94.94
6	Exceptional items	(189.90)	22.73	12.47	754.08
7	Profit/(Loss) before tax (5-6)	-	577.84	-	(577.84)
8	Tax expenses :	(189.90)	(555.11)	12.47	176.24
	Current tax- current year	-	(103.16)	3.14	46.33
	prior year	-	-	-	-
	Deferred tax liability/ (asset)	-	-	-	-
9	Profit/ (Loss) for the period (7-8)	(189.90)	(451.95)	9.33	129.91
10	Other Comprehensive Income - (OCI) -(net of tax)	689.02	(775.20)	25.40	(1,024.08)
11	Total Comprehensive Income/(Expense) for the period (9+10)	499.12	(1,227.15)	34.74	(894.17)
12	Paid-up equity share capital (face value of Rs.1/- each)	1,441.50	1,441.50	480.50	1,441.50
13	Reserves and Surplus excluding Revaluation reserves	4,416.82	4,606.72	1,633.55	4,606.72
14	Basic & Diluted earning per share (face value of Rs.1/- each)*	(0.13)	(0.48)	0.02	0.14
13	Basic & Diluted Earning Per Share after extraordinary items (face value of Rs.1/- each)	(0.13)	(0.48)	0.02	0.14

* Not annualised, except year end basic and diluted EPS

Notes :-

- The above results of the Company were reviewed by the Audit Committee and approved by the Board of Directors in its meeting held on 13/08/2026.
- Figures of the previous period/year have been regrouped wherever necessary to conform to the current period/year presentation.
- The Company has two business segment, disclosure under Ind AS 108 on "Segment Reporting" issued by the ICAI is applicable to Company.



For Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)



Narayan Singh Rathore
Managing Director
DIN : 10900646

Place: Udaipur,
Dated: 13th August, 2026

DEEP HEALTH AI INDIA LIMITED

Formerly Known as "DEEP DIAMOND INDIA LIMITED"

Regd. Office: 506-509, fifth floor, Apeksha, Plot No.256, Main Road, Hiran Magri, Sector-11, Udaipur, Rajasthan (313001)

CIN: L24100RJ1994PLC112895

E-Mail: deephealthaiindia@gmail.com

Website: www.deephealthaiindia.com

Segment Reporting (Standalone)

The Company is responsible for Segment reporting as per IndAS -108 "Operating Segment" specified under section 133 of the Companies Act, 2013. As the Company is engaged in two segments viz. Jewellery of Gold and Diamond Studded and Marketing of Pharmaceutical goods in India.

(Rs. In Lacs)		
Particulars	Quarter Ended June 30, 2026 (Unaudited)	Year Ended March 31, 2026 (Audited)
1. Segment Revenue (Income) (Net sale/income from each segment should be disclosed)		
Jewellery Business	0.00	0.00
Pharmaceutical Business	45.00	425.00
Less: Intersegment revenue	0.00	0.00
Revenue from operations	45.00	425.00
2. Segment Results		
Jewellery Business	0.00	0.00
Pharmaceutical Business	-205.81	332.77
Add: Other Income	16.61	424.02
Total Profit before tax	-189.20	756.79
i. Finance Cost	0.70	2.71
ii. Other Unallocable Expenditure net off Unallocable income	0.00	-577.84
3. Profit before Tax and Exceptional Items	-189.90	754.08
4. Exceptional Items	0.00	-577.84
5. Profit before Tax	-189.90	176.24
4. Current Tax - Current year	0.00	46.33
5. Profit after Tax	-189.90	129.91
6. Share of Profit / (Loss) from Associate Co / Joint Venture	0.00	0.00
7. Other Comprehensive Income	689.02	-1024.08
8. Profit after OCI	499.12	-894.17
9. Segment Asset		
Jewellery Business	51.46	51.46
Pharmaceutical Business	165.69	940.38
other Income	0.00	0.00
Total Segment Asset	217.15	991.84
Un-allocable Assets	5505.78	4233.21
Net Segment Asset	5722.93	5225.05
10. Segment Liabilities		
Jewellery Business	0.00	0.00
Pharmaceutical Business	0.00	0.00
other Income	0.00	0.00
Total Segment Liabilities	0.00	0.00
Un-allocable Liabilities	5722.93	5225.05
Net Segment Liabilities	5722.93	5225.05



Place: Udaipur.

Dated: 13th August, 2026

For Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)



Narayan Singh Rathore
Managing Director
DIN: 10900646

DEEP HEALTH AI INDIA LIMITED

Formerly Known as "DEEP DIAMOND INDIA LIMITED"

Regd. Office: 506-509, fifth floor, Apeksha, Plot No.256, Main Road, Hiran Magri, Sector-11, Udaipur, Rajasthan

CIN: L24100RJ1994PLC112895

E-Mail: deephealthaiindia@gmail.com

Website: www.deephealthaiindia.com

NOTES: -

1) The Company has presented its **Standalone** Financial Results under Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these **Standalone** financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial results for the comparative previous period have also been presented in accordance with the recognition and measurement principles laid down in the Ind AS 34.

2) The above Standalone financial results have been reviewed and recommended by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on August 13, 2026.

3) The financial results and other financial / segment information for the quarter ended June 30, 2026 have already been audited or reviewed by the Statutory Auditors and are presented based on the information compiled by the management, after exercising necessary due diligence and making the necessary adjustments to give a true and fair view of the results in accordance with Ind AS.

4) Reconciliation of Net Profit on account of transition from previous GAAP to Ind AS for the quarter ended June 30, 2026:

5) (Rs. in Lacs)

Description	Quarter Ended 30 th June 2026	Year Ended 31 st March 2026
Net Profit / (Loss) as per previous GAAP (Indian GAAP)	-189.90	129.91
Fair Value gain on Financial Instrument	-	-
Other	-	-
Profit / (Loss) for the Quarter/Year as per IND AS	-189.90	129.91
Other Comprehensive Income (Net of Income Tax)	689.02	-1024.08
Total Comprehensive Profit / (Loss) for the quarter/Year	499.12	-894.17


6) During the Quarter there was no complaint from the Investors.

7) Figures of the Corresponding previous period have been regrouped, rearranged wherever necessary to conform to the classification of the current period

8) The Company has two reportable segments (i.e., Pharmaceuticals and Gems & Jewellery). Disclosure under Ind AS 108 on "Segment Reporting" issued by the ICAI is applicable to Company.

For Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)




Narayan Singh Rathore
Managing Director
DIN: 10900646

Place: Udaipur

Dated: 13th August, 2026





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to,
**The Board Of Directors,
Deep Health AI India Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/s. DEEP HEALTH AI INDIA LIMITED** (the "Company"), for the quarter ended June 30th, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of Entity	Relationship
Deep HEALTH AI INDIA LIMITED	Parent Company
Ferry Automotive Private Limited	Associate Company

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



The Statement includes the interim financial results and other financial information of an associate company whose interim financial results/information reflects share of loss of associate concern amounting to Rs. 24.92 Lacs for the quarter ended June 30, 2026. These financial statements are unaudited and have been furnished to us by the management and our opinion in so far as it relates to the amounts and disclosures included in respect of these associates is based solely on the information and explanation provided by the management. Our conclusion on the Statement is not modified in respect of the above matter.

For **V R S K & CO. LLP**
(Formerly known as V R S K. & Co.)
CHARTERED ACCOUNTANTS
Firm Regn. No: 111426W/W100988



Suresh G. Kothari
Partner
Membership No: 047625



Place : Mumbai
Date : August 13th 2026
UDIN : 26047625TNDKUZ7866

DEEP HEALTH AI INDIA LIMITED

Formerly Known as "DEEP DIAMOND INDIA LIMITED"

Regd. Office: 506-509, fifth floor, Apeksha, Plot No.256, Main Road, Hiran Magri, Sector-11, Udaipur, Rajasthan (313001)

CIN: L24100RJ1994PLC112895

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue from operations	45.00	25.00	15.00	425.00
	-Jewellery Business	-	-	-	-
	-Pharmaceutical Business	45.00	25.00	15.00	425.00
2	Other income	16.61	18.22	18.68	424.02
3	Total income (1+2)	61.61	43.22	33.68	849.02
4	Expenses				
	a) Cost of material consumed	-	-	-	-
	b) Purchase of Stock -in-Trade	-	-	-	-
	c) Changes in inventories of finished goods work-in-progress and Stock -in-Trade	-	-	-	-
	d) Employee benefits expense	4.81	5.89	4.14	18.81
	e) Finance costs	0.70	0.73	0.74	2.71
	f) Depreciation	0.12	0.16	0.27	0.81
	g) Other expenses	245.88	13.79	16.06	72.64
	Total expenses	251.51	20.57	21.21	94.97
5	Profit/ (Loss) before exceptional items and tax (3-4)	(189.90)	22.65	12.47	754.05
6	Exceptional items	-	577.17	-	577.17
	Share of Profit / (Loss) from Associate Co	(24.92)	0.66	(2.96)	(17.16)
	Share of Profit / (Loss) from Joint Venture	-	-	-	-
7	Profit/(Loss) before tax (5-6)	(214.82)	(553.86)	9.51	159.72
8	Tax expenses :				
	Current tax- current year	-	(103.16)	3.14	46.33
	prior year	-	-	-	-
	Deferred tax liability/ (asset)	-	-	-	-
9	Profit/ (Loss) for the period (7-8)	(214.82)	(450.70)	6.37	113.39
10	Other Comprehensive Income - (OCI) -(net of tax)	689.02	(775.19)	25.40	(1,024.07)
11	Total Comprehensive Income/(Expense) for the period (9+10)	474.20	(1,225.89)	31.77	(910.68)
12	Paid-up equity share capital (face value of Rs.1/- each)	1,441.50	1,441.50	480.50	1,441.50
13	Reserves and Surplus excluding Revaluation reserves	4,392.56	4,607.38	1,630.59	4,589.56
14	Basic & Diluted earning per share (face value of Rs.1/- each)*	(0.15)	(0.48)	0.01	0.12
13	Basic & Diluted Earning Per Share after extraordinary items (face value of Rs.1/- each)	(0.15)	(0.48)	0.01	0.12

* Not annualised, except year end basic and diluted EPS

Notes :-

- The above results of the Company were reviewed by the Audit Committee and approved by the Board of Directors in its meeting held on 13th August, 2026.
- Figures of the previous period/year have been regrouped wherever necessary to conform to the current period/year presentation.
- The Company has two business segment, disclosure under Ind AS 108 on "Segment Reporting" issued by the ICAI is applicable to Company.



Place: Udaipur,
Dated: 13th August, 2026



For Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)

Narayan Singh Rathore
Managing Director
DIN : 10900646

DEEP HEALTH AI INDIA LIMITED

Formerly Known as "DEEP DIAMOND INDIA LIMITED"

Regd. Office: 506-509, fifth floor, Apeksha, Plot No.256, Main Road, Hiran Magri, Sector-11, Udaipur, Rajasthan
(313001)

CIN: L24100RJ1994PLC112895

E-Mail: deephealthaiindia@gmail.com

Website: www.deephealthaiindia.com

Segment Reporting (Consolidated)

The Company is responsible for Segment reporting as per IndAS -108 "Operating Segment" specified under section 133 of the Companies Act, 2013. As the Company is engaged in two segments viz. Jewellery of Gold and Diamond Studded and Marketing of Pharmaceutical goods in India.

(Rs. In Lacs)

Particulars	Quarter Ended June 30, 2026 (Unaudited)	Year Ended March 31, 2026 (Audited)
1. Segment Revenue (Income) (Net sale/income from each segment should be disclosed)		
Jewellery Business	0.00	0.00
Pharmaceutical Business	45.00	425.00
Less: Intersegment revenue	0.00	0.00
Revenue from operations	45.00	425.00
2. Segment Results		
Jewellery Business	0.00	0.00
Pharmaceutical Business	-205.81	332.74
Add: Other Income	16.61	424.02
Total Profit before tax	-189.20	756.76
i. Finance Cost	0.70	2.71
ii. Other Unallocable Expenditure net off Unallocable income	0.00	0.00
3. Profit before Tax and Exceptional Items	-189.90	754.05
4.Exceptional Items	0.00	-577.17
5.Profit before Tax	-189.90	176.88
6. Current Tax - Current year	0.00	46.33
7. Profit after Tax	-189.90	130.55
7. Share of Profit / (Loss) from Associate Co / Joint Venture	-24.92	-17.16
8. Other Comprehensive Income	689.02	-1024.07
9. Profit after OCI	474.20	-910.68
10. Segment Asset		
Jewellery Business	51.46	51.46
Pharmaceutical Business	165.59	940.38
other Income	0.00	0.00
Total Segment Asset	217.05	991.84
Un-allocable Assets	5480.96	4216.05
Net Segment Asset	5698.01	5207.89
11. Segment Liabilities		
Jewellery Business	0.00	0.00
Pharmaceutical Business	0.00	0.00
other Income	0.00	0.00
Total Segment Liabilities	0.00	0.00
Un-allocable Liabilities	5698.01	5207.89
Net Segment Liabilities	5698.01	5207.89

For Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)



Narayan Singh Rathore
Managing Director
DIN: 10900646



Place: Udaipur
Dated: 13th August, 2026

DEEP HEALTH AI INDIA LIMITED

Formerly Known as "DEEP DIAMOND INDIA LIMITED"

Regd. Office: 506-509, fifth floor, Apeksha, Plot No.256, Main Road, Hiran Magri, Sector-11, Udaipur, Rajasthan (313001)

CIN: L24100RJ1994PLC112895

E-Mail: deephealthaiindia@gmail.com

Website: www.deephealthaiindia.com

NOTES: -

- 1) The Company has presented its **Consolidated** Financial Results under Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these **Consolidated** financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial results for the comparative previous period have also been presented in accordance with the recognition and measurement principles laid down in the Ind AS 34.
- 2) The above Consolidated financial results have been reviewed and recommended by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on August 13, 2026.
- 3) The financial results and other financial / segment information for the quarter ended June 30, 2026 have already been audited or reviewed by the Statutory Auditors and are presented based on the information compiled by the management, after exercising necessary due diligence and making the necessary adjustments to give a true and fair view of the results in accordance with Ind AS.
- 4) Reconciliation of Net Profit on account of transition from previous GAAP to Ind AS for the quarter ended June 30, 2026:

5)

(Rs. in Lacs)

Description	Quarter Ended 30 th June 2026	Year Ended 31 st March 2026
Net Profit / (Loss) as per previous GAAP (Indian GAAP)	-214.82	113.39
Fair Value gain on Financial Instrument	-	-
Other	-	-
Profit / (Loss) for the Quarter/Year as per IND AS	-214.82	113.39
Other Comprehensive Income (Net of Income Tax)	689.02	-1024.07
Total Comprehensive Profit / (Loss) for the quarter/Year	474.20	-910.68

- 6) During the Quarter there was no complaint from the Investors.
- 7) Figures of the Corresponding previous period have been regrouped, rearranged wherever necessary to conform to the classification of the current period
- 8) The Company has two reportable segments (i.e., Pharmaceuticals and Gems & Jewellery). Disclosure under Ind AS 108 on "Segment Reporting" issued by the ICAI is applicable to Company.

Place: Udaipur

Dated: 13th August, 2026

For Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)




Narayan Singh Rathore
Managing Director
DIN: 10900646

